SSA
ABBV icon

Schonfeld Strategic Advisors’s AbbVie ABBV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,500
Closed -$5.83M – 2152
2025
Q4 		$5.83M Buy
+25,500
New +$5.81M 0.03% 499
2025
Q2 		– Sell
-18,300
Closed -$3.83M – 1981
2025
Q1 		$3.83M Buy
+18,300
New +$3.56M 0.02% 632

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schonfeld Strategic Advisors's ABBV Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its AbbVie (ABBV) stake by 164% in Q1 2026, buying an estimated $7.31M and bringing the position to 53,060 shares worth $11.5M. The position accounts for 0.08% of the portfolio, ranked #266.

Schonfeld Strategic Advisors first reported a position in ABBV in Q3 2016 and has held it in 34 quarters since. The position peaked at $12.3M in Q2 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Schonfeld Strategic Advisors held 53,060 shares of AbbVie worth $11.5M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 32,932 AbbVie shares in Q1 2026, an estimated $7.31M.
  • AbbVie made up 0.08% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #266 holding.
  • Schonfeld Strategic Advisors first reported a position in AbbVie in Q3 2016 and has held it in 34 quarters since.
  • Schonfeld Strategic Advisors's AbbVie position peaked at $12.3M in Q2 2021.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.